Antitumor drug with double active components and application thereof

A technology of anti-tumor drugs and active ingredients, applied in the field of anti-tumor drugs, can solve the problems of unsatisfactory tumor treatment effects, and achieve clear and significant anti-tumor effects, significant anti-tumor activity, and enhanced inhibitory effects

Active Publication Date: 2011-09-28
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI +1
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] Experiments have proved that the effect of using the above drugs alone is not very satisfactory for tumor treatment. Therefore, ho...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor drug with double active components and application thereof
  • Antitumor drug with double active components and application thereof
  • Antitumor drug with double active components and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Recipe: Dipyridamole is 1mg, 5mg, 50mg, 100mg, 200mg, 400mg, 800mg or 1600mg respectively, Ubenimex is 1mg, 10mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1600mg or 3200mg respectively. Pyridamole and Ubenimex are stirred and mixed.

Embodiment 2

[0063] Recipe: dipyridamole is 1mg, 5mg, 50mg, 100mg, 200mg, 400mg, 800mg or 1600mg respectively, and dexamethasone is 0.1mg, 1mg, 10mg, 20mg, 40mg, 80mg or 160mg respectively. Stir dipyridamole and dexamethasone together.

Embodiment 3

[0065] Recipe: Ubenimex is 1mg, 10mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1600mg or 3200mg respectively, and dexamethasone is 0.1mg, 1mg, 10mg, 20mg, 40mg, 80mg or 160mg respectively. Stir Ubenimex and Dexamethasone to mix.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antitumor drug with double active components, and an application thereof. The antitumor drug comprises an independent first active component and an independent second active component. The independent first active component comprises at least two of A, B and C. The A comprises Dipyridamole and pharmaceutically acceptable derivatives of Dipyridamole or pharmaceutically acceptable analogues of Dipyridamole or pharmaceutically acceptable salts of Dipyridamole. The B comprises Ubenimex bestatin and pharmaceutically acceptable derivatives of Ubenimex bestatin or pharmaceutically acceptable analogues of Ubenimex bestatin or pharmaceutically acceptable salts of Ubenimex bestatin. The C comprises Dexamethasone and pharmaceutically acceptable derivatives of Dexamethasone or pharmaceutically acceptable analogues of Dexamethasone. The independent second active component comprises Taxol, ADM, DDP, MMC, 5-FM, Gemcitabine or a tyrosine kinase inhibitor. The antitumor drug provided by the invention can effect on multiple targets and multiple paths, and thus antineoplastic effects of the antitumor drug are clear and obvious.

Description

technical field [0001] The invention relates to a medicine with antitumor effect, in particular to an antitumor medicine comprising dipyridamole, ubenimex and dexamethasone and an antitumor chemotherapeutic medicine. Background technique [0002] The toxicity of currently clinically used antitumor drugs is a prominent problem in tumor chemotherapy. Finding its own low toxicity and acting on specific links or molecular targets in the tumor microenvironment to improve the anti-tumor effect or reduce its toxicity has become a new way to study anti-tumor drugs, and it is also an urgent need for clinical treatment of tumors. [0003] Malignant tumor is a common disease that seriously threatens human health. In today's world, there is an urgent need for anti-tumor drugs. According to the data in 2007, there were 12 million newly diagnosed cancer patients in the world, and 7.6 million people died of cancer. According to the data of the top ten disease mortality and cause of deat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/24A61K31/704A61K31/573A61K31/519A61K31/513A61K31/407A61K31/337A61K31/198A61K45/00A61P35/00
Inventor 刘秀均甄永苏郑艳波李毅吴淑英
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products